{
  "docId": "019de076-39d2-7099-ad19-065ffc77ed59",
  "docSlug": "e110bee9f1b318f547399ddf66ee5ee3",
  "documentTitle": "Exscientia | Results Presentation Deck | 24 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 24,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-39d2-7099-ad19-065ffc77ed59/23",
  "deckHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59",
  "deckJsonHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59.json",
  "deckAnchorHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.41,
        "x": 0.077,
        "y": 0.23
      },
      "kind": "list",
      "text": "Internal pipeline: Focus on differentiated, high value oncology targets; Enrollment ongoing in ELUCIDATE Phase 1/2 trial for CDK7 inhibitor; LSD1 inhibitor preparing for clinical start in 1H24; New preclinical data for LSD1 and MALT1 inhibitors presented at ESMO 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e18d04f-2712-49b1-a66f-ad106ba076f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.41,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "list",
      "text": "Technology updates: Presented data on automated kinase method; Novel automated discovery laboratory opened in Milton Park",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "856aa0d9-db06-497b-bcaf-70caf64b9c54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.41,
        "x": 0.077,
        "y": 0.65
      },
      "kind": "list",
      "text": "Precision medicine: EXCYTE-1 ongoing trial in ovarian cancer; Collaboration with Charité to evaluate precision medicine in haematological cancers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "861b2b99-0787-4b1c-ad5b-c7383d1eef75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.41,
        "x": 0.52,
        "y": 0.23
      },
      "kind": "list",
      "text": "Partnered programmes: AI drug discovery collaboration with Merck KGaA; First milestone achieved in Sanofi collaboration; EXS4318, a PKC-theta inhibitor, is continuing in a Phase 1 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e885fa93-3624-4e5f-8a83-48e26d45c0d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.285,
        "x": 0.077,
        "y": 0.067
      },
      "kind": "title",
      "text": "2023 Highlights YTD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4486214-37a5-431c-acf6-5beaf6f6b83f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 20,
      "beatId": "447a7f6d-2cc1-4538-a8f4-356a57ceac2a",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Key Messages",
      "beatSlug": null,
      "evidence": "The document highlights key messages and financials, emphasizing its strategy and portfolio expansion",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}